Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The healthcare company's forecast for 2026 tops Wall Street's expectations. ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros. ...

U.S. stock futures rose on Wednesday following Tuesday’s sharp sell-off. Futures of major benchmark indices were higher.On Tuesday, the S&P 500 index recorded its worst session since October 2025, dipping more than 2% during the session as risk-off sentiment intensified following President Donald Trump's aggressive new trade stance toward Europe. Trump threatened several European countries with additional tariffs starting Feb. 1 if negotiations over Greenland control fail, with duties potentially rising to ...

2026 年 1 月， Johnson & Johnson MedTech 宣布，在美国市场正式推出 Arbrea Breast Simulator Surgeon App for Mentor 。该产品是一款面向整形外科医生的 移动端数字化咨询工具 ，可运行于平板和智能手机， 用于乳房手术（尤其是隆乳手术）的术前沟通与方案展示。 从定位上看，该应用并非手术器械或术中系统，而是服务于 医患沟通与决策前端 的数字工具，目标在于提 升咨询阶段的可视化程度与沟通效率。 3. 实时辅助医生与患者讨论 医生可在咨询过程中动态展示不同方案的潜在效果，支持更结构化的方案对比与讨论，而非单向讲解。 从 技术属性上看，该产品属于 数字健康与三维可视化软件 ，并未涉及术中导航或治疗决策。 # 了解 A rbrea （ 一 ） 功能与技术特点拆解 根据强生 MedTech 的公开说明，Arbrea 应用的核心功能集中在以下几个方面： 1. 快速生成个性化 3D 模拟结果 应用可在约 60 秒内 生成患者个性化的三维模拟效果，用于展示不同隆乳方案可能带来的外观变化。 2. 替代传统"物理尺码 + 图片库"的沟通方式 强生指出，目前多 ...

Market Analysis by covering: S&P 500, Johnson & Johnson. Read 's Market Analysis on Investing.com ...

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Johnson & Johnson (NYSE:JNJ) to report quarterly earnings at $2.46 per share on revenue of $24.16 billion before the opening bell, according to data from Benzinga Pro. Johnson & Johnson shares slipped 0.3% to $217.50 in after-hours trading.GameStop Corp. (NYSE:GME) shares rose in Tuesday's extended trading after CEO Ryan Cohen disclosed a massive purchase ...

Johnson & Johnson (NYSE:JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.Analysts expect the company to report fourth-quarter earnings of $2.47 per share. That’s up from $2.04 per share in the year-ago period. The consensus estimate for Johnson & Johnson’s quarterly revenue is $24.16 billion (it reported $22.52 billion last year), according to Benzinga Pro.As per the recent news, Johnson & Johnson, on Jan. 14, shared topline results from the investigational Pha ...

Earnings Report - Johnson & Johnson is set to release its fourth-quarter earnings on January 21, with analysts expecting earnings of $2.47 per share, an increase from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, up from $22.52 billion reported last year [1] Clinical Study Update - On January 14, Johnson & Johnson shared topline results from the Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer [2] - Following this news, shares of Johnson & Johnson fell by 0.2%, closing at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and raised the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and increased the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]